TLR2 and focal segmental glomerulosclerosis: In a rat model of FSGS using 5/6 nephrectomy, the inhibition of TLR2 and TLR 4 with the small-molecule lecinoxoids VB-201 and VB-703, respectively, is sufficient to improve FSGS outcomes and reduces the number of glomerular and interstitial monocytes [194].